anti-CD33 CAR T-cell therapy (Zhongyuan Union Cell & Gene Engineering)

N/A

Report date: 2025/03/14 16:31:42

Base Information

Drug Nameanti-CD33 CAR T-cell therapy (Zhongyuan Union Cell & Gene Engineering)
Drug Alias Nameanti-CD33 CAR T-cell therapy (Heyuan Biotechnology/Zhongyuan Union Cell & Gene Engineering)anti-CD33 CAR T-cell therapy (Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHematology Hospital Of Chinese Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesJuventas Cell Therapy Ltd
Inactive CompaniesHematology Hospital Of Chinese Academy Of Medical SciencesVcanbio Cell & Gene Engineering Corp Ltd
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A